<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332198</url>
  </required_header>
  <id_info>
    <org_study_id>2019_A02882_55</org_study_id>
    <nct_id>NCT04332198</nct_id>
  </id_info>
  <brief_title>Neurobiological and Immunological Mechanisms of Dyspnea in ALS</brief_title>
  <official_title>Neurobiological and Neuro-immunological Mechanisms of Dyspnea in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea; subjective experience of respiratory discomfort; which produces negative emotional
      experience, is the most common symptom of patients afflicted with chronic respiratory failure
      and its treatments are limited. Amyotrophic Lateral Sclerosis (ALS) related - dyspnea, due to
      diaphragmatic dysfunction, is similar to dyspnea during mechanical inspiratory load
      (activation of the supplementary motor area, SMA). The perception of pain and dyspnea is
      processed in similar brain areas (insula, dorsal anterior cingulate cortex, amygdala and
      medial thalamus) and in ALS; relieving dyspnea by noninvasive ventilation (NIV) is associated
      with decreased pain thresholds. Otherwise, it is reported systemic elevations of
      pro-inflammatory cytokines in chronic pain patients, correlating with intensity of pain, and
      during respiratory load in healthy volunteers.

      The objectives are to evaluate the cytokines and endorphins rates variations after initiation
      of NIV in ALS patients, and to correlate cytokines and endorphins rates with the intensity of
      the affective component and the intensity of the sensory component of dyspnea.

      The investigators will perform a prospective, experimental study, including 30 ALS patients.
      Dyspnea, ventilatory and cardiac settings, electromyographic recording of the scalene muscle
      and biological assays (ACTH, endorphin, Neuropeptide P, BDNF, IL1, IL6, IL8, IL10, TNF), will
      be measured during spontaneous breathing and during NIV at different times after initiation.

      The investigators expect a reduction of immunological and neurobiological markers after
      relieving dyspnea by NIV. This work could lead to the development of new treatments for
      dyspnea.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the cytokines and endorphins rates variation after initiation of NIV in ALS patients</measure>
    <time_frame>30 minutes</time_frame>
    <description>measure cytokines and endorphins blood levels before and after NIV</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Shortness of Breath</condition>
  <condition>Dyspnea</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biological test</intervention_name>
    <description>dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation</description>
    <arm_group_label>ALS patients</arm_group_label>
    <other_name>questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients with chronic respiratory failure with diaphragmatic dysfunction linked to
        amyotrophic lateral sclerosis and requiring long-term NIV

        Exclusion Criteria:

          -  Other respiratory disease (COPD, asthma, obstructive sleep apnea)

          -  Alcohol or psychotropic drug the lasts 24 hours

          -  Cognitive impairment

          -  Smoking &gt; 10 PA

          -  Exacerbation or infection 6 weeks earlier

          -  Endstage of illness

          -  Chronic or acute pain (VAS &gt; 3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>March 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

